Incyte

🇺🇸United States
Ownership
-
Employees
2.5K
Market Cap
$12.6B
Website
Introduction

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Clinical Trials
Related News

A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma

First Posted Date
2008-03-19
Last Posted Date
2018-02-13
Lead Sponsor
Incyte Corporation
Target Recruit Count
13
Registration Number
NCT00639002

Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer

Phase 2
Terminated
Conditions
Prostate Cancer
Interventions
Drug: Ruxolitinib
First Posted Date
2008-03-19
Last Posted Date
2018-02-12
Lead Sponsor
Incyte Corporation
Target Recruit Count
22
Registration Number
NCT00638378

Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis

Phase 2
Completed
Conditions
Psoriasis
Interventions
Drug: Ruxolitinib
First Posted Date
2008-02-18
Last Posted Date
2022-02-08
Lead Sponsor
Incyte Corporation
Target Recruit Count
25
Registration Number
NCT00617994

A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis

Phase 2
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: INCB018424
Drug: Placebo
First Posted Date
2007-10-26
Last Posted Date
2015-03-23
Lead Sponsor
Incyte Corporation
Target Recruit Count
50
Registration Number
NCT00550043

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

First Posted Date
2007-08-01
Last Posted Date
2018-03-12
Lead Sponsor
Incyte Corporation
Target Recruit Count
154
Registration Number
NCT00509899

Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects

First Posted Date
2007-05-24
Last Posted Date
2016-12-06
Lead Sponsor
Incyte Corporation
Target Recruit Count
24
Registration Number
NCT00478322

A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes

Phase 1
Completed
Conditions
Insulin Resistance
Obesity
First Posted Date
2006-11-14
Last Posted Date
2012-01-23
Lead Sponsor
Incyte Corporation
Registration Number
NCT00398619

Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients

Phase 2
Completed
Conditions
HIV Infections
Interventions
Drug: INCB009471
Drug: Placebo comparator
First Posted Date
2006-10-26
Last Posted Date
2018-03-26
Lead Sponsor
Incyte Corporation
Target Recruit Count
45
Registration Number
NCT00393120

Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs

First Posted Date
2006-03-09
Last Posted Date
2018-08-23
Lead Sponsor
Incyte Corporation
Target Recruit Count
250
Registration Number
NCT00300573
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy